These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36214713)

  • 1. Central GPR55 may prevent nicotine reinforcing actions: a preliminary study.
    Díaz-Barba A; Calvillo-Robledo A; Vázquez-León P; Gallegos-Vieyra E; Quintanar JL; Marichal-Cancino BA
    Acta Neurobiol Exp (Wars); 2022; 82(3):304-314. PubMed ID: 36214713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysophosphatidylinositol Promotes Chemotaxis and Cytokine Synthesis in Mast Cells with Differential Participation of GPR55 and CB2 Receptors.
    Martínez-Aguilar LM; Ibarra-Sánchez A; Guerrero-Morán DJ; Macías-Silva M; Muñoz-Bello JO; Padilla A; Lizano M; González-Espinosa C
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GPR55 activation prevents amphetamine-induced conditioned place preference and decrease the amphetamine-stimulated inflammatory response in the ventral hippocampus in male rats.
    Sánchez-Zavaleta R; Segovia J; Ruiz-Contreras AE; Herrera-Solís A; Méndez-Díaz M; de la Mora MP; Prospéro-García OE
    Prog Neuropsychopharmacol Biol Psychiatry; 2023 Jan; 120():110636. PubMed ID: 36099968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson's disease rat model.
    Fatemi I; Abdollahi A; Shamsizadeh A; Allahtavakoli M; Roohbakhsh A
    Acta Neuropsychiatr; 2021 Feb; 33(1):15-21. PubMed ID: 32967746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoid receptor GPR55 activation blocks nicotine use disorder by regulation of AMPAR phosphorylation.
    Liu Q; Yu J; Li X; Guo Y; Sun T; Luo L; Ren J; Jiang W; Zhang R; Yang P; Yang Q
    Psychopharmacology (Berl); 2021 Nov; 238(11):3335-3346. PubMed ID: 34648060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55.
    Yamashita A; Oka S; Tanikawa T; Hayashi Y; Nemoto-Sasaki Y; Sugiura T
    Prostaglandins Other Lipid Mediat; 2013 Dec; 107():103-16. PubMed ID: 23714700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A putative lysophosphatidylinositol receptor GPR55 modulates hippocampal synaptic plasticity.
    Hurst K; Badgley C; Ellsworth T; Bell S; Friend L; Prince B; Welch J; Cowan Z; Williamson R; Lyon C; Anderson B; Poole B; Christensen M; McNeil M; Call J; Edwards JG
    Hippocampus; 2017 Sep; 27(9):985-998. PubMed ID: 28653801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of GPR55, a putative cannabinoid receptor.
    Sharir H; Abood ME
    Pharmacol Ther; 2010 Jun; 126(3):301-13. PubMed ID: 20298715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysophosphatidylinositol causes neurite retraction via GPR55, G13 and RhoA in PC12 cells.
    Obara Y; Ueno S; Yanagihata Y; Nakahata N
    PLoS One; 2011; 6(8):e24284. PubMed ID: 21904624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?
    Nevalainen T; Irving AJ
    Curr Top Med Chem; 2010; 10(8):799-813. PubMed ID: 20370712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.
    Sharir H; Console-Bram L; Mundy C; Popoff SN; Kapur A; Abood ME
    J Neuroimmune Pharmacol; 2012 Dec; 7(4):856-65. PubMed ID: 22454039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPR18 and GPR55-related Ligands Serving as Antagonists or Agonists: Current Situation, Challenges and Perspectives.
    Zhang L; Fang Y; Hang S; Wu W; Sheng R; Guo R
    Med Chem; 2023; 19(9):838-847. PubMed ID: 37038675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids.
    Anavi-Goffer S; Baillie G; Irving AJ; Gertsch J; Greig IR; Pertwee RG; Ross RA
    J Biol Chem; 2012 Jan; 287(1):91-104. PubMed ID: 22027819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central administration of GPR55 receptor agonist and antagonist modulates anxiety-related behaviors in rats.
    Rahimi A; Hajizadeh Moghaddam A; Roohbakhsh A
    Fundam Clin Pharmacol; 2015 Apr; 29(2):185-90. PubMed ID: 25620584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Activity Relationship of the GPR55 Antagonist, CID16020046.
    Brown AJ; Castellano-Pellicena I; Haslam CP; Nichols PL; Dowell SJ
    Pharmacology; 2018; 102(5-6):324-331. PubMed ID: 30296786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Crucial Amino Acid Residues Involved in Agonist Signaling at the GPR55 Receptor.
    Lingerfelt MA; Zhao P; Sharir HP; Hurst DP; Reggio PH; Abood ME
    Biochemistry; 2017 Jan; 56(3):473-486. PubMed ID: 28005346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca(2+) release in rat mesenteric artery endothelial cells.
    AlSuleimani YM; Hiley CR
    Br J Pharmacol; 2015 Jun; 172(12):3043-57. PubMed ID: 25652040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of GPR55 increases neural stem cell proliferation and promotes early adult hippocampal neurogenesis.
    Hill JD; Zuluaga-Ramirez V; Gajghate S; Winfield M; Persidsky Y
    Br J Pharmacol; 2018 Aug; 175(16):3407-3421. PubMed ID: 29888782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysophosphatidylinositol Induced Morphological Changes and Stress Fiber Formation through the GPR55-RhoA-ROCK Pathway.
    Nakajima K; Oka S; Tanikawa T; Nemoto-Sasaki Y; Matsumoto N; Ishiguro H; Arata Y; Sugiura T; Yamashita A
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oncogenic lysophosphatidylinositol (LPI)/GPR55 signaling.
    Calvillo-Robledo A; Cervantes-Villagrana RD; Morales P; Marichal-Cancino BA
    Life Sci; 2022 Jul; 301():120596. PubMed ID: 35500681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.